Eli Lilly and Company (LLY) Financials
LLY Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 63.9 billion | 51.0 billion |
2023-12-31 | 64.0 billion | 53.1 billion |
2023-09-30 | 57.9 billion | 46.6 billion |
2023-06-30 | 54.8 billion | 43.7 billion |
LLY Free Cash Flow and Stock based compensation
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | 179.7 million | 159.4 million |
2023-12-31 | -2.0 billion | 120.2 million |
2023-09-30 | -1.8 billion | 215.6 million |
2023-06-30 | -204.4 million | 161.5 million |
LLY Net Income
Date | Net Income |
---|---|
2024-03-31 | 2.2 billion |
2023-12-31 | 2.2 billion |
2023-09-30 | -57.4 million |
2023-06-30 | 1.8 billion |
LLY Cash and Debt
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | 2.6 billion | - | - |
2023-12-31 | 2.9 billion | - | - |
2023-09-30 | 2.5 billion | 17.9 billion | - |
2023-06-30 | 2.8 billion | 18.2 billion | - |
LLY Shares Outstanding
LLY Expenses
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 986.3 million | 2.5 billion | 1.8 billion | 116.1 million |
2023-12-31 | 1.7 billion | 2.6 billion | 1.5 billion | 461.9 million |
2023-09-30 | 4.0 billion | 2.4 billion | 1.8 billion | - |
2023-06-30 | 836.3 million | 2.4 billion | 1.9 billion | - |
LLY Cost of Revenue
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 8.8 billion | 1.5 billion |
2023-12-31 | 9.4 billion | 1.7 billion |
2023-09-30 | 9.5 billion | 1.9 billion |
2023-06-30 | 8.3 billion | 1.8 billion |
LLY
List: Contenders
Price: $832.59
Dividend Yield: 0.68%
Forward Dividend Yield: 0.62%
Payout Ratio: 76.92%
Dividend Per Share: 5.20 USD
Earnings Per Share: 6.76 USD
P/E Ratio: 133.87
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Volume: 2.6 million
Ebitda: 758.9 millionMarket Capitalization: 728.7 billion
Average Dividend Frequency: 4
Years Paying Dividends: 53
DGR3: 15.07%
DGR5: 14.29%
DGR10: 8.16%
DGR20: 6.24%